arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Celldex Therapeutics, Inc.

CLDX Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances
$39.68
Today
as of Sep 4, 16:47 ET
Last 30 days +11.52% Jul 28 → Sep 04
$34.84 $37.53 $40.23 $42.92 $45.61 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$38.96
High
$39.81
Low
$38.90
Volume
$414,529
Avg Vol
$934,961
Mkt Cap
$3.3B
P/E (TTM)
—
Beta
—
52w High
$45.14
52w Low
$22.10
Div Yield
—
Shares Out
$79M

Recent Press Releases & News last 60 days · 17 items

Aug 9 · 06:13 Simply Wall St.
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results
Aug 9 · 04:24 Simply Wall St.
Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?
Aug 9 · 02:08 Simply Wall St.
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return
▸ Show all 17 press releases & news Free account →

Overview

52-week range
$22
$45
76% of range
Avg surprise (last 3)
-4.7%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
110%
EM ±17.2% · $40 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.18$-1.02$-0.86$-0.70$-0.54 Actual $-0.62Actual $-0.65Actual $-0.81Actual $-0.56Actual $-0.54Actual $-0.64Actual $-0.81Est $-0.75Actual $-0.85Est $-0.86Actual $-1.01Actual $-1.18Est $-1.10Actual $-0.94 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-79M$-58M$-38M$-17M$3M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.94 — — — — financials
Thu May 7, 2026Mar/2026 $-1.18 $-1.10 -7.3% -45.7% -3.1% earnings
Tue Sep 30, 2025Sep 2025 $-1.01 — — — — financials
Thu Aug 7, 2025Jun/2025 $-0.85 $-0.86 +1.2% — — earnings
Thu May 8, 2025Mar/2025 $-0.81 $-0.75 -8.0% — +3.2% earnings
Mon Sep 30, 2024Sep 2024 $-0.64 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.54 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.56 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.81 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.65 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.62 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$22,000$15,000——$730,000$695,000—$3M
Cost of revenue————————
Gross profit————————
Operating income$-81M$-84M—$-74M$-64M$-63M—$-52M
Net income$-74M$-79M—$-67M$-57M$-54M—$-42M
EPS (diluted)$-0.94$-1.18—$-1.01$-0.85$-0.81—$-0.64

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$47M$36M$29M$36M$23M$17M$28M$36M
Inventory————————
Total current assets$725M$459M$535M$604M$648M$694M$747M$779M
Total assets$782M$511M$583M$648M$692M$739M$792M$823M
Long-term debt————————
Total liabilities$68M$55M$56M$50M$37M$36M$45M$37M
Total equity$715M$456M$527M$598M$655M$703M$747M$786M

Implied volatility — last 90 days

39%103%168%232%296% Jun 07 — IV 112% · EM ±15.5%Jun 09 — IV 121% · EM ±15.1%Jun 11 — IV 59% · EM ±6.5%Jun 12 — IV 56% · EM ±5.8%Jun 15 — IV 54% · EM ±3.9%Jun 16 — IV 134% · EM ±7.9%Jun 17 — IV 242% · EM ±10.1%Jun 19 — IV 63% · EM ±14.0%Jun 22 — IV 45% · EM ±9.4%Jun 23 — IV 57% · EM ±11.6%Jun 24 — IV 58% · EM ±11.6%Jun 25 — IV 67% · EM ±13.1%Jun 26 — IV 65% · EM ±12.5%Jun 29 — IV 59% · EM ±10.5%Jun 30 — IV 50% · EM ±8.6%Jul 01 — IV 50% · EM ±8.4%Jul 02 — IV 86% · EM ±13.9%Jul 03 — IV 89% · EM ±13.9%Jul 06 — IV 58% · EM ±8.0%Jul 07 — IV 74% · EM ±9.8%Jul 08 — IV 71% · EM ±8.9%Jul 09 — IV 97% · EM ±11.4%Jul 13 — IV 95% · EM ±7.9%Jul 15 — IV 220% · EM ±13.0%Jul 16 — IV 101% · EM ±4.2%Jul 20 — IV 54% · EM ±12.7%Jul 21 — IV 112% · EM ±26.1%Jul 22 — IV 53% · EM ±12.0%Jul 23 — IV 62% · EM ±14.0%Jul 24 — IV 48% · EM ±10.6%Jul 27 — IV 73% · EM ±15.3%Jul 29 — IV 39% · EM ±7.9%Jul 30 — IV 42% · EM ±8.3%Jul 31 — IV 53% · EM ±10.1%Aug 04 — IV 43% · EM ±7.4%Aug 05 — IV 90% · EM ±15.1%Aug 10 — IV 71% · EM ±9.8%Aug 11 — IV 54% · EM ±7.1%Aug 12 — IV 70% · EM ±8.7%Aug 13 — IV 46% · EM ±5.4%Aug 14 — IV 70% · EM ±7.7%Aug 17 — IV 99% · EM ±8.2%Aug 18 — IV 101% · EM ±7.3%Aug 19 — IV 122% · EM ±7.2%Aug 20 — IV 297% · EM ±12.4%Aug 24 — IV 70% · EM ±14.7%Aug 25 — IV 64% · EM ±13.0%Aug 26 — IV 83% · EM ±16.6%Aug 27 — IV 64% · EM ±12.5%Aug 28 — IV 75% · EM ±14.3%Aug 31 — IV 69% · EM ±12.3%Sep 01 — IV 78% · EM ±13.4%Sep 02 — IV 80% · EM ±13.4%Sep 03 — IV 88% · EM ±14.2%Sep 04 — IV 110% · EM ±17.2%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in